Compare EXEL & SITM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXEL | SITM |
|---|---|---|
| Founded | 1994 | 2003 |
| Country | United States | United States |
| Employees | N/A | 441 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 10.4B |
| IPO Year | 2000 | 2019 |
| Metric | EXEL | SITM |
|---|---|---|
| Price | $45.40 | $406.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 7 |
| Target Price | $46.45 | ★ $390.71 |
| AVG Volume (30 Days) | ★ 2.0M | 325.6K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.95 | 57.53 |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $452,477,000.00 | $326,660,000.00 |
| Revenue This Year | $13.66 | $49.65 |
| Revenue Next Year | $13.39 | $27.77 |
| P/E Ratio | $15.89 | ★ N/A |
| Revenue Growth | N/A | ★ 61.16 |
| 52 Week Low | $33.76 | $123.59 |
| 52 Week High | $48.74 | $446.96 |
| Indicator | EXEL | SITM |
|---|---|---|
| Relative Strength Index (RSI) | 67.32 | 61.94 |
| Support Level | $40.53 | $327.71 |
| Resistance Level | $45.88 | $444.22 |
| Average True Range (ATR) | 0.99 | 22.83 |
| MACD | 0.38 | 8.64 |
| Stochastic Oscillator | 95.50 | 99.59 |
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
SiTime Corp is a provider of Precision Timing solutions to the international electronics industry, providing the timing functionality needed for electronics to operate reliably and correctly. The Company's products are designed to address a wide range of applications across a broad array of end markets. The Company operates a fabless business model and leverages its international network of distributors to address the end markets it serves. The Company operates in one reportable segment related to the design, development, and sale of silicon timing systems solutions. It operates in Hong Kong, Taiwan, the United States, Singapore, and other regions, with the majority of revenue coming from Hong Kong.